Pharmaceutical Technology

APRIL 4, 2023

Formerly known as CTX001, exa-cel is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy. Vertex Pharmaceuticals chief medical officer and Global Medicines Development and Medical Affairs executive vice-president Carmen Bozic said: “The completion of our exa-cel global regulatory filings is a historic milestone. “We

Gene Therapy 246

Gene Therapy Gene Editing In-Vivo Gene 246

Pharmaceutical Technology

FEBRUARY 23, 2023

It covers a broad range of techniques from the less invasive practice of intermittent fasting to drastic and invasive procedures, such as the implanting of microchips or injecting of gene-editing enzymes. nurses, doctors, and hospital auxiliary staff) to meet these needs.

Gene Editing 278

Gene Editing Regulation Production Nurses 278

XTalks

FEBRUARY 10, 2023

Medpace has IP experience with both autologous and allogeneic cellular products, ex vivo and in vivo gene transfer, and a number of different gene-editing mechanisms. An overview of Medpace’s experience in conducting cell and gene therapy trials. Extensive knowledge of regional and country specific requirements.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene Therapy 52

The Pharma Data

NOVEMBER 16, 2020

The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov. 16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus.

Vaccination 52

Vaccination Vaccine Immune Response Genetics 52